Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | RET | P07949 | 11/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344810 | 0.93 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2266354 | 0.88 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2540739 | 0.87 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2271405 | 0.86 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL1411271 | 0.86 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL1411700 | 0.86 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL1411565 | 0.86 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2343760 | 0.86 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2344267 | 0.86 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL2347234 | 0.85 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.